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Abstract: An artificial neural network was used to optimize the release of salbutamol 
sulfate from hydrophilic matrix formulations. Model formulations to be used for training, 
testing and validating the neural network were manufactured with the aid of a central 
composite design with varying the levels of Methocel® K100M, xanthan gum, Carbopol® 
974P and Surelease® as the input factors. In vitro dissolution time profiles at six different 
sampling times were used as target data in training the neural network for formulation 
optimization. A multi layer perceptron with one hidden layer was constructed using 
Matlab®, and the number of nodes in the hidden layer was optimized by trial and error to 
develop a model with the best predictive ability. The results revealed that a neural network 
with nine nodes was optimal for developing and optimizing formulations. Simulations 
undertaken with the training data revealed that the constructed model was useable. The 
optimized neural network was used for optimization of formulation with desirable release 
characteristics and the results indicated that there was agreement between the predicted 
formulation and the manufactured formulation. This work illustrates the possible utility of 
artificial neural networks for the optimization of pharmaceutical formulations with 
desirable performance characteristics.  
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1. Introduction 
Pharmaceutical formulations are complex systems in which the properties and performance 
characteristics are influenced by numerous formulation and process factors that may not be easily 
understood. Pharmaceutical optimization has been defined as the implementation of systematic 
approaches to establish the best possible combination of materials and/or process variables under a 
given set of conditions that will result in the production of a quality pharmaceutical product with 
predetermined and specified characteristics each time it is manufactured [1]. The use of artificial 
intelligence such as artificial neural networks (ANN) is a rapidly growing field in knowledge 
discovery and data mining and has been applied in the pharmaceutical sciences for the development 
and optimization of dosage forms [2–7]. 
ANN are computational tools that emulate the interconnected neurological structures of the human 
brain and the ability of the human brain to learn and solve problems through pattern recognition [2]. 
ANN simulate the learning behavior of the human brain by modeling data and recognizing patterns for 
complicated multi-dimensional relationships that exist between input and output or target sets of data. 
Once trained an ANN can be used to predict and forecast outputs for a given a set of input conditions 
and may therefore be used to optimize both formulation and process variables in order to engineer and 
manufacture high quality, safe and effective dosage forms [8]. 
The most commonly used network architecture for pharmaceutical applications is the multi-layer 
perceptron, which consists of three layers, viz., an input, hidden and output layer. Each layer has a 
number of neurons or nodes that are fully interconnected with neurons in the neighboring layers as 
shown in Figure 1. 
The input layer consists of one or more input nodes or processing elements that distribute input data 
to nodes located in the hidden layer of the ANN. Each node in the input layer can represent an 
independent variable, for example, an amount of polymer in a formulation or machine operating 
conditions such as compression force for a tablet press. The input layer does not process any 
information, but serves as a distribution point for information to be delivered to the hidden layer. The 
hidden layer can be made up of one of more layers of parallel nodes (Figure 1 shows one layer). The 
nodes in the hidden layer perform a weighted summation of the inputs followed by a non-linear 
transformation, which then relays that data to the output layer. The number of nodes in the hidden 
layer is critical to the efficiency of a network and if the hidden layer has too few nodes, the ANN will 
lack the power needed to classify the data provided to it. Conversely, if there are too many nodes, 
patterns in the input data will be memorized and therefore the ability of the network to interpolate data 
will be diminished [9,10]. The output nodes represent measureable properties of pharmaceutical 
formulations and may include parameters such as, for example, tablet hardness or percent drug 
released at different stages of a dissolution test [9–11].  
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Figure 1. MLP architecture for a feed forward back propagation ANN where x1 – x4 are 
inputs and y1 and y2 represent response factors [8,9]. 
 
 
The usefulness of neural networks for formulation optimization has been reported [3–6,12–16] and 
different strategies may be use used for formulation optimization. Several authors have reported the 
use of formulation variables such as the level of excipients used in a formulation as input or causal 
factors and the percent drug released at different stages of a dissolution test as response factors for 
ANN [5,14,15]. However, Takayama et al. [5] and Ibric et al. [16] used response factors from 
dissolution models to train networks and to optimize pharmaceutical formulations where it was 
reported that the predicted values from an ANN model were found to be in close agreement with those 
of experimentally generated data. Ibric et al. [16] used a generalized regression neural network to 
optimize sustained release formulation compositions for aspirin. The amount of polymer and the 
compression pressure were used as causal factors and the in vitro dissolution test sampling time points 
and Korsmeyer–Peppas model parameters were used as response factors. Formulation optimization 
using ANN models has also been performed using a generalized distance function with optimal drug 
release parameters being used as response factors [5]. The f1 or difference and f2 or similarity fit factors 
are typically used for the comparison of experimentally generated and predicted in vitro dissolution 
profiles when conducting optimizations with ANN models [14,16].  
Data from experimental design methodologies are often used to construct ANN models since the 
experimental design approach usually ensures independence of the formulation factors used to evaluate 
a system [6]. The use of experimental design for developing training data for ANN has been reported 
and includes the use of a three factor, three level, central composite design [17], two-factor spherical 
second order composite experimental design [12] and a four component simplex centroid mixture 
design [8]. The use of empirical data from experimental design methods was therefore considered 
suitable for formulation optimization.  
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Hydrophilic monolithic matrix devices are a popular choice for the manufacture of sustained release 
solid oral dosage forms due to their ease of manufacture and the extensive amount of information 
available regarding this well understood technology. The use of hydrophilic matrix formulations to 
control the release of drugs from pharmaceutical tablets is well documented [18–21]. The rate and 
mechanism of drug release from monolithic devices can be adjusted by the levels and types of polymer 
combinations that are used to manufacture a formulation.  
When hydrophilic matrix tablets are immersed in aqueous media, the polymer hydrates, swells and 
increases in size after which the matrix dissolves and/or erodes with time [22,23]. Early studies have 
shown that drug release from swellable hydrophilic matrices is dependent on the thickness of the 
hydrated gel layer that is formed during the swelling phase of polymer hydration [22,23]. The degree 
of swelling determines the diffusional path length of a drug and the thicker the gel layer the slower the 
rate of drug release from a matrix [24]. Drug release from hydrophilic matrix formulations occurs by 
drug diffusion through the gel layer and/or erosion of the tablet matrix.  
Hydroxypropyl methylcellulose (HPMC) has been used extensively for the manufacturing of tablets 
[25–31], although other matrix forming materials including Carbopol® [32–34] and xanthan gum 
[18,24] have also been used. The use of Surelease®, an aqueous dispersion of ethylcellulose as a 
granulating fluid, has also been reported, where it has been shown to retard drug release from 
monolithic matrix formulations [35,36]. These materials were investigated as potential excipients, in 
combination to control the rate of salbutamol sulfate release from hydrophilic matrix tablets.  
Salbutamol sulfate, a short-acting β2 agonist, is a water-soluble salt of salbutamol that is used for 
the treatment of bronchoconstriction and bronchospasm in patients with reversible obstructive airway 
disease and chronic obstructive pulmonary disease [37,38]. Salbutamol sulfate was selected as a model 
low-dose water soluble drug because it is stable in aqueous media and light and therefore useful for 
studying the impact of formulation variables on dosage performance characteristics.  
The objective of this study was to develop an optimized hydrophilic matrix formulation for 
salbutamol sulfate with an in vitro release profile that was similar to a reference formulation, viz., 
Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, India). The levels of Methocel® K100M, xanthan 
gum, Carbopol® 974P and Surelease® as the granulating fluid were varied using formal experimental 
design, specifically a central composite design and the formulation was optimized using ANN to 
develop a formulation with a similar in vitro dissolution profile to that of the reference formulation. In 
addition, the ANN architecture was optimized by analyzing the efficiency of ANN that have different 
numbers of nodes in the hidden layer and to investigate the feasibility of using the f2 similarity factor 
for formulation optimization.  
2. Experimental Section  
2.1. Materials  
Salbutamol sulfate was donated by Aspen-Pharmacare (Port Elizabeth, Eastern Cape, SA). 
Methocel® K100M (HPMC) (Dow Chemical Company, Midland, MI, USA), Avicel® PH101 (FMC 
BioPolymer, Philadelphia, PA, USA), xanthan gum (Aspen-Pharmacare, Port Elizabeth, Eastern Cape, 
SA), Surelease® (Colorcon, West Point, PA, USA), Carbopol® 974P NF (Lubrizol, Wickliffe, OH, 
USA), magnesium stearate (Aspen-Phamacare, Port Elizabeth, Eastern Cape, SA) and colloidal silica 
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(Aspen-Pharmacare, Port Elizabeth, Eastern Cape, SA) were used as received. All other reagents were 
at least of analytical reagent grade and used as received. 
2.2. Experimental design  
A central composite design for formulation optimization was generated using the Model Based 
Calibration Toolbox of Matlab® R2008a (MathWorks Inc., Natick, MA, USA) and was used for 
studying the impact of chosen formulation variables on the extent of drug release from matrix 
formulations. The independent variables, viz., the amounts of Methocel® K100M, xanthan gum, 
Carbopol® 974P and percent composition of Surelease® as the granulating fluid that were assessed are 
listed in Table 1, which shows the randomized order in which the formulations were manufactured and 
subsequently analyzed. In vitro release data from the central composite design was used to train the 
ANN for formulation optimization.  
Table 1. Formulation compositions of hydrophilic matrix tablets generated using a central 
composite design.  
Formulation Methocel® K100M 
(mg) 
Xanthan gum 
(mg) 
Carbopol® 974P 
(mg) 
Surelease® 
(% w/w) 
SAL001 120 50 10 12 
SAL002 60 50 10 12 
SAL003 60 50 10 4 
SAL004 60 50 20 12 
SAL005 90 75 15 16 
SAL006 60 50 10 20 
SAL007 90 25 15 16 
SAL008 30 75 15 16 
SAL009 60 50 10 12 
SAL010 90 75 5 8 
SAL011 0 50 10 12 
SAL012 30 25 5 16 
SAL013 60 50 10 12 
SAL014 30 25 15 8 
SAL015 60 50 10 12 
SAL016 60 100 10 12 
SAL017 90 75 5 16 
SAL018 30 25 15 16 
SAL019 90 25 5 8 
SAL020 90 75 15 8 
SAL021 30 75 5 16 
SAL022 30 25 5 8 
SAL023 30 75 5 8 
SAL024 90 25 15 8 
SAL025 60 50 0 12 
SAL026 90 25 5 16 
SAL027 60 0 10 12 
SAL028 60 50 10 12 
SAL029 60 50 10 12 
SAL030 30 75 15 8 
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2.3. Manufacture of sustained release matrix tablets 
Surelease® is a 25% w/w aqueous dispersion of ethylcellulose. Surelease® was diluted for use as the 
granulating liquid and dispersion were prepared by accurately weighing the correct amount of 
dispersion on a top loading balance (Mettler Toledo Inc., Columbus, OH, USA) and diluting by weight 
with HPLC-grade water to concentrations of 4, 8, 12, 16 and 20% w/w. Batch sizes of 1000 tablets 
were manufactured for each formulation. Matrix tablets were manufactured by dry blending 
salbutamol sulfate and the appropriate quantities of Methocel® K100M, xanthan gum, Carbopol® 974P 
and Avicel® PH101 in a Saral® Rapid Mixer and Granulator (Saral Engineering Company, Mumbai, 
Maharashtra, India) in a 5 L bowl using a speed of 100 rpm on the main impeller for 15 min. 
Thereafter, 120 g of Surelease® diluted to the desired concentration with water (4–20% w/w) was 
gradually sprayed onto the powder blend using a manual spray. The bed was agitated using speeds of 
120 rpm and 1000 rpm for the main impeller and chopper, respectively. The wet mass was mixed for 
an additional 5 min at the same speed and removed from the granulator and allowed to dry on wax 
paper for 24 h at a temperature of 22 ºC. Thereafter, the granules were sieved and the fraction between 
315 and 800 mm was collected and weighed, after which magnesium stearate and colloidal silica 
equivalent of 1% w/w and 0.5% w/w, respectively, were sieved and added to the blend that was mixed 
for a further 3 min at 100 rpm using the main impeller only. Finally, the lubricated granules were 
compressed into tablets using 9 mm biconvex punches on a Manesty® B3B rotary tablet press to a 
uniform weight of 220 mg.  
2.4. In vitro dissolution studies  
A VanKel® Bio-Dis dissolution apparatus (VanKel Industries, Edison, NJ, USA) was used for the 
assessment of the in vitro release characteristics of salbutamol sulfate formulations. A model VK 750D 
digitally controlled water circulation/heater (VanKel Industries, Edison, NJ, USA) was used to 
maintain the temperature of the dissolution medium at 37 ± 0.5 ºC. A mesh of pore size 177 µm was 
used to retain the dosage form in the inner tubes and a dip speed of 10 dpm was used as the agitation 
rate. The dosage forms were maintained in 200 mL of buffers at pH 1.2, 4.5, 6.0 for 1, 1 and 2 h 
respectively and at pH 6.8 for the rest of the dissolution test and samples were collected after 1, 2, 4, 6, 
8 and 12 h from commencement of the dissolution studies.  
A 2 mL aliquot of dissolution medium was removed from the dissolution vessels using an electronic 
pipette (Boeckel & Co (GmbH & Co), Hamburg, Hamburg, Germany) and filtered through a 0.45 µm 
Millipore® filter (Millipore, Bedford, MA, USA). A 1.5 mL aliquot was placed in a sample vial and  
100 µL of a terbutaline sulfate solution (400 µg/mL) was added to the vial such that the final 
concentration of the internal standard was approximately 25 µg/mL. The samples were analyzed using 
a validated HPLC method to determine the percent drug released at different stages of the  
dissolution test. 
HPLC analysis was performed using a modular HPLC system that consisted of a Model P100 dual 
piston pump (Thermo Separation Products, San Jose, CA, USA), a Model AS100 autosampler 
(Thermo Separation Products, San Jose, CA, USA), which was equipped with a Rheodyne® Model 
7010 injector (Rheodyne, Reno, NV, USA) fitted with a 20 µL fixed volume loop and a 250 µL 
GASTIGHT® Model 1725 syringe (Hamilton Co., Reno, NV, USA), a Linear UV/VIS-500 Model 
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6200-9060 detector (Linear Instrument Co., CA, USA); and a Spectra Physics SP 4600 integrator 
(Thermo Separation Products, San Jose, CA, USA). Separation was achieved under isocratic 
conditions using a mobile phase consisting of 20% v/v ACN in 18 mM phosphate buffer at pH = 4, 
containing 15 mM sodium octane sulphonate and a Phenomenex® Hyperclone® column, 5 μm, 150 mm 
× 4.6 mm (Phenomenex, Torrance, CA, USA) at ambient temperature (22 ºC). Samples were 
monitored by UV detection at 220 nm. The volume of injection was 20 μL and a flow rate of 1.0 
mL/min was used for the separation. 
2.5. Artificial neural network  
Commercially available software, Matlab® R2008a (MathWorks Inc., Natick, MA, USA), was used 
to write mathematical code for training and evaluating the ANN developed and used for formulation 
optimization. 
A neural network composed of an input and output layer with one hidden layer, i.e., a three-layer 
back propagation network was chosen for the purposes of this study. Four input factors corresponding 
to different levels of Methocel® K100M (x1), xanthan gum (x2), Carbopol® 974P (x3) and Surelease® 
(x4) were used as units in the input layer of the ANN. The data generated from the central composite 
design was used as the training set for the ANN. The percent drug dissolved at different stages of the 
dissolution test (n = 6) was used as output the layers or the target data during ANN training. 
Specifically, yih = % salbutamol sulfate released, such that i = 1, 2, 4, 6, 8 and 12 h. There were 180  
(30 × 6) input-target data pairs that were used to train, test and validate the neural network. The data 
was split into three categories, viz., the training, test and validation data sets, where 67% of the data set 
was used for training and 33% as the test data. The validation set was selected from the test data and 
constituted 67% the test data set.  
The input and target data from in vitro dissolution testing was initially randomized to allow for 
efficient training of the network. Prior to training, the mapminmax function was used to scale the 
inputs and targets so that the values for these fell within a range of -1 to +1 based on the highest and 
lowest values in the data sets. Scaling the factors to this range is useful for efficient training of the 
network since it prevents bias in training if some of the values are significantly bigger or smaller than 
the other values in the training data set. If mapminmax is used to scale the target value, then the 
output of the network will be trained to produce outputs in the range -1 to +1 and these must then be 
converted back to original values by using the reverse of this function.  
A sigmoidal function (logsig) (Equation 1) was used as the transfer function for the hidden layer 
and back propagation of errors.  
                                                    (1) 
Where,  = sum of the input to the node. A purelin function was used for the output layer. The 
Levenberg–Marquardt algorithm for back-propagation with a gradient descent and momentum weight 
and bias learning function, was used to train the network. The Mean Squared Error (MSE) was used as 
the performance function and training was terminated after either 200 validation failures or 800 epochs 
or iterations of the network, whichever came first.  
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Activation of the neural network was achieved by simulating the neural network using normalized 
training data. A post-process activation on the predicted data set was then required to convert it back to 
the original input range. In the final step, the predicted data was then compared with the original data 
set by plotting the predicted versus original values and computing the correlation coefficient for each 
of the responses in the output layer. These results were then compared, and the closer the value was to 
1 then the better the predictive capability of the model. Several training sessions with different 
numbers of nodes (3–10) in the hidden layer were conducted in order to resolve the optimal ANN 
structure and each of these models were compared in this way. The optimal network architecture was 
then selected for further application and this final model was retrained with the entire data set to obtain 
a network model that could be used for formulation optimization and further simulations.  
2.6. Optimization procedure  
Formulation optimization was conducted using the f2 similarity factor (Equation 2) [39] for the 
comparison of dissolution profiles.  
 
                          (2) 
 
Where, n = is the number of dissolution sample times, t = the time sample index, Rt = the mean 
percent dissolved at time t for the reference dissolution profile and Tt = the mean percent dissolved at 
time t for the test dissolution profile. Functions for formulation optimization using simulation of the 
trained ANN and the f2 similarity factor were written in the Matlab® editor (Mathworks Inc., Natick, 
MA, USA). All possible permutations of the formulation variables, viz., Methocel® K100M, xanthan 
gum, Carbopol® 974P and Surelease®, within the experimental domain were generated using a brute 
force method and were then simulated using the trained ANN. The resultant simulated profiles were 
compared with the dissolution profiles of the reference formulation, Asthalin®8 ER (Cipla Ltd., 
Mumbai, Maharashtra, India). The function was used to determine the formulation that had the highest 
value for similarity. This formulation was subsequently manufactured and dissolution testing was 
conducted using USP Apparatus 3 as previously described.  
3. Results and Discussion  
3.1. In vitro dissolution testing 
The dissolution test results are shown in Figures 2 and 3 for the formulations manufactured using 
the central composite design. The dissolution profiles that were generated were subsequently used to 
train, test and validate the neural network.  
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Figure 2. In vitro mean dissolution profiles of formulations SAL001 – SAL015 established 
from experimental design.  
 
Figure 3. In vitro mean dissolution profiles of formulations SAL016 – SAL030 established 
from experimental design.  
 
 
The in vitro dissolution profiles depicted in Figures 2 and 3 reveal that approximately  
25–47% of the dose is released within an hour of commencing dissolution testing and the remaining 
drug is gradually released over the next 11 h. After 12 h of dissolution testing, the percent release from 
all formulations ranges between approximately 83% to complete drug release. The rate of release is 
fairly rapid in the beginning of the dissolution test, but the rate of release decreases as the dissolution 
test progresses. This type of release is typical of drug release of water soluble drugs such as salbutamol 
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sulfate, which display time-dependent release kinetics that are characterized by a diffusion controlled 
mechanism. 
3.2. Training and testing ANN  
The number of nodes in the hidden layer that are required to produce a good predictive network 
depends on the complexity of the problem to be solved, the number of nodes in both the input and 
output layers, and the size of the training data set. Furthermore, the amount of noise in the target data, 
network architecture, the required accuracy of the prediction and the training algorithm that is used are 
also important factors that determine the number of nodes that are required in the hidden layer [6]. The 
number of nodes in the hidden layer is of paramount importance when constructing an ANN model, 
and having too few hidden nodes decreases the learning ability of a network whereas too many hidden 
nodes may result in over-fitting or memorization of the training data set and a reduced ability of a 
network to generalize and predict accurately [6].  
Although several approaches, including Kolmogorov’s theorem [40] and Carpenter and Hoffman’s 
Equation [41] have been proposed as suitable to determine the number of nodes to be included in a 
hidden layer of an ANN, a trial and error approach is often selected [6,42]. The trial and error 
approach was used to determine the optimal number of nodes for inclusion in the network, and the 
situation that produced the highest range of R2 values for each of the response factors was selected as 
the optimal architecture to use.  
The impact of changing the number of nodes in the hidden layer of an ANN on the predictive 
ability of the ANN is depicted in Figure 4.  
Figure 4. The impact of the number of nodes in the hidden layer of an ANN on the 
correlation coefficient at different stages of the dissolution test. 
 
 
Inspection of Figure 4 reveals that the efficiency of the network is dependent on the number of 
nodes in that network. It is clearly evident that the optimal number of nodes in the hidden layer for this 
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system is nine, since this architecture produces the highest overall value of R2 for all stages of the 
dissolution test data. As the number of nodes is increased to above nine, it is also apparent that there is 
a decrease in the efficiency of the network, which is likely due to overtraining of the network.   
The results reveal that when a neural network that had nine nodes in the hidden layer was used, the 
lowest or best validation error was observed at epoch 317 and was equivalent to 0.0249. The low error 
indicates that the model may be used to accurately predict the relationship between input and target 
data pairs and may therefore be used for prediction of outputs given a set of inputs. The correlation 
data for each of the different data points are summarized in Table 2. 
Table 2. Correlation of output factors. 
Output factor  R2 
% Release after 1 h  0.9366 
% Release after 2 h 0.9501 
% Release after 4 h 0.9366 
% Release after 6 h 0.9508 
% Release after 8 h 0.9181 
% Release after 12 h 0.8323 
 
The results from the prediction of test data generated by the ANN vs. the experimentally determined 
or observed values in the test data set are shown in Figure 5.  
Figure 5. Comparison of correlation coefficients for predicted vs. observed data. 
 
 
These results show that an ANN that has nine nodes in the hidden layer has good predictive 
capabilities and therefore may be used for formulation optimization and simulation of the impact of 
formulation variables on the dissolution rate of salbutamol sulfate from hydrophilic matrix 
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formulations. The network was therefore trained with all data and was used for the formulation 
optimization exercise.  
3.3. Simulation ability of the neural network  
A function for simulating the in vitro release profile for hypothetical formulations was written in 
Matlab® code (Mathworks Inc., Natick, MA, USA) and used to simulate different in vitro release 
profiles. This strategy was adopted as it would be useful to determine the predictive ability of the 
trained network and to establish whether the network could be used to predict “unseen” data within a 
data set. For example, the network could be used to test a posed question such as “What would the 
percent drug dissolved at the different dissolution time points be from a formulation that contains 30 
mg Methocel® K100M, 75 mg xanthan gum, 5 mg Carbopol® 974P that was granulated using a 16% 
w/w solution of Surelease®?” (provided that all the other factors and processing parameters were kept 
constant). The neural network is then asked to find the corresponding solution to the posed question 
and the percent drug released after 1, 2, 4, 6, 8 and 12 h would be 32.5%, 43.4%, 60.9%, 74.4%, 
85.8% and 96.4% respectively. The corresponding in vitro release profile that was obtained for the 
manufactured formulation with the same composition revealed that 32.6%, 43.6%, 60.7%, 74.3%, 
85.1% and 96.2% of salbutamol sulfate were released at the same time points. The in vitro dissolution 
profile that was generated using the simulation function was compared using the f2 similarity factor, 
which indicated that the profiles were indeed similar because a value of 94.6 was calculated.  
3.4. Optimization results  
The brute force method was used to predict the composition of a hydrophilic matrix formulation 
with the desirable release characteristics similar to the reference formulation, Asthalin®8 ER (Cipla 
Ltd., Mumbai, Maharashtra, India). A summary of the proposed formulation composition is listed in 
Table 3, including the predicted in vitro release data and the f2 similarity factor for that hypothetical 
formulation.  
Table 3. Optimization formulation.   
Formulation  Predicted dissolution profile 
Methocel® K100M  45 mg y1h 38.38% 
Xanthan gum  30 mg y2h 49.95% 
Carbopol® 974P 5 mg y4h 65.87% 
Surelease®  10% w/w y6h 80.00% 
Avicel® PH101 105.1 mg  y8h 87.00% 
Colloidal silica 0.5% w/w y12h 95.00% 
Magnesium stearate  1% w/w f2 factor  90.5 
 
The in vitro dissolution profile generated for the optimized formulation following manufacture is 
shown in comparison with the predicted and reference formulations in Figure 6.  
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Figure 6. In vitro release profile of the optimized formulation compared with the reference 
formulation, Asthalin® 8 ER. 
 
 
It is evident that there are similarities between the dissolution profiles of the manufactured 
formulation and that of Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, India) tablets. The f2 
similarity factor was calculated to be 86.0. The correlation between the manufactured formulation 
derived from the optimization procedure using ANN and that for the predicted formulation is shown in 
Figure 7. The results show that the relationship between the predicted and observed formulations was 
nearly linear showing excellent predictability for the optimization by use of ANN. 
Figure 7. Percent drug release for the optimized vs. predicted formulation with y = x – 2.5 
and R2 = 0.9964. 
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4. Summary and Conclusions  
Matlab® R2008a (Mathworks Inc., Natick, MA, USA) was used to write code for the training and 
evaluation of a neural network. Formulation variables and in vitro dissolution profiles from a central 
composite study were used for training, testing and validating the network models that were 
developed.  
The efficiency of the network was dependent on the number of nodes in the hidden layer and the 
numbers of nodes were tested by means of a trial and error approach using between three and ten 
neurons. The optimal number of nodes that produced a good predictive model was nine. Once the 
number of nodes had been established, the data was once again used to train a network that was then 
applied to the optimization of a sustained release matrix formulation for salbutamol sulfate.  
The f2 similarity factor was used to establish whether formulation optimization had been successful 
by comparing ANN predicted dissolution profiles to that generated from the reference formulation, 
Asthalin®8 ER (Cipla Ltd., Mumbai, Maharashtra, India). A brute force method was applied to 
generate permutations for simulation into the model and the combination of formulation variables that 
resulted in the highest f2 value was selected. The resultant model formulation was then manufactured 
using a wet granulation procedure. The resultant formulation was found to perform satisfactorily and 
an f2 value of 86.0 was calculated for the comparison, clearly indicating that the dissolution profiles 
were similar. These results demonstrate the potential utility of ANN models for formulation 
development and optimization. Defining dosage form performance criteria from the outset is vitally 
important in developing a model formulation with the desired physical and quality characteristics.  
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